What is Newomics?
Newomics is at the forefront of developing innovative solutions for liquid chromatography-mass spectrometry (LC-MS). Their product portfolio, including the UniESI system and MEA chip, is engineered to enhance sensitivity and throughput in critical analytical processes. The company's technology serves a diverse range of applications, from clinical diagnostics and biomarker discovery to drug development and environmental monitoring, positioning Newomics as a key player in the multiomics technology sector. Their commitment to plug-and-play compatibility and robust performance aims to accelerate scientific research and clinical applications.
How much funding has Newomics raised?
Newomics has raised a total of $11.9M across 3 funding rounds:
Series A
$3.9M
Debt
$150K
Series B
$7.9M
Series A (2018): $3.9M with participation from Undisclosed
Debt (2020): $150K led by PPP
Series B (2020): $7.9M supported by Photon Fund, LDV Partners, Berkeley Catalyst Fund, and MSA Capital
Key Investors in Newomics
LDV Partners
LDV Partners is dedicated to transforming innovative ideas into successful companies by collaborating closely with visionary founders. They provide strategic insights, hands-on support, and essential resources to foster growth in disruptive technologies. Their portfolio includes companies like Neuralink and SpaceX, focusing on advancements in AI and life sciences. LDV Partners aims to empower entrepreneurs to redefine industries and create a significant impact.
Berkeley Catalyst Fund
Berkeley Catalyst Fund is a venture capital firm. It provides benefits to entrepreneurial startups. The company is based in Cupertino, California.
MSA Capital
Founded in 2014, MSA Capital is an independent global private equity and venture capital firm with over $1.5 billion under management. MSA actively partners with outstanding entrepreneurs globally to build leading, innovative companies that aim to deliver strong financial returns and meaningful, positive social impacts.
What's next for Newomics?
With the recent major strategic investment, Newomics is poised for accelerated scaling and further innovation in the LC-MS market. The substantial enterprise-level funding indicates a strong market validation and provides the necessary capital to expand its technological capabilities and market reach. Future developments are likely to focus on enhancing the performance of their existing product lines and potentially exploring new applications within the rapidly evolving fields of proteomics, metabolomics, and clinical mass spectrometry. This strategic financing will be instrumental in solidifying Newomics' position as a leader in advanced analytical instrumentation.
See full Newomics company page
